纵向MRD监测可增强105例接受同步放化疗的局限期SCLC患者的预后预测 Longitudinal MRD Monitoring Enhances Prognosis Prediction in 105 Patients with Limited-Stage SCLC Receiving Concurrent Chemoradiotherapy 讲者:杨燕教授(中国医学科学院肿瘤医院) MA17.06 度伐利尤单抗联合安罗替尼与度伐利尤单抗作为ES-SCLC维持治疗的比...
参考文献 [1] Shibayama, Takuo, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung cancer 32.1 (2001): 61-69. [2] Tumour markers in lung cancer: EGTM recommendations. Eur...
The log-rank test and multivariate Cox proportional hazard regression model were utilized to evaluate clinical prognosis. Results All patients were aged 59. 6 years old on average, and the female proportion was 23%. The quantity of brain metastasis lesion was 1 in 35%, 2-3 in 23% and ≥...
The log-rank test and multivariate Cox proportional hazard regression model were utilized to evaluate clinical prognosis. ResultsAll patients were aged 59.6 years old on average, and the female proportion was 23%. The quantity of brain metastasis lesion was 1 in 35%, 2-3 in 23% and ≥4 ...
in small cell lung cancer has been growing because of multiple factors, including the expanded use of surveillance brain magnetic resonance imaging (MRI), evolving controversies surrounding prophylactic cranial irradiation (PCI), integration of immunotherapy into management, and improvements in prognosis.9...
Then there’s a cohort of choice who want to hear their prognosis delivered directly and understand that the treatment options aren’t very good. As we’re discussing, there’s a lot of toxicity associated with those options. Hossein Borghaei, DO, MS: Vivek, if somebody has evidence of ...
(BM) at the initial diagnosis and eventually up to 40%-50% developing BM during the course of their disease [3]. Some reported prognostic factors include performance status (PS), increased age, male gender, and numerous metastatic sites at baseline [4]. But certainly, prognosis is largely ...
The most common sites of metastasis include the brain, liver, and bone [6]. SCLC has known pathologic, clinical, and molecular characteristics [7]. Prognosis remains poor, and without active treatment, median survival is 2–4 months; even with treatment, less than 5% of patients survive for...
[1] Shibayama, Takuo, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung cancer 32.1 (2001): 61-69. [2] Tumour markers in lung cancer: EGTM recommendations. European Grou...
Small cell lung cancer is an aggressive high-grade neuroendocrine tumor associated with a short doubling time, a high growth fraction, and early development of widespread metastases, which contribute to the extremely poor disease prognosis. These aspects of SCLC, as well as the limited success of ...